SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/04/18 Morgan Stanley 10-Q 3/31/18 131:34M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 2.15M 2: EX-10.1 Material Contract HTML 116K 3: EX-12 Statement re: Computation of Ratios HTML 59K 4: EX-15 Letter re: Unaudited Interim Financial Info HTML 47K 5: EX-31.1 Certification -- §302 - SOA'02 HTML 43K 6: EX-31.2 Certification -- §302 - SOA'02 HTML 43K 7: EX-32.1 Certification -- §906 - SOA'02 HTML 38K 8: EX-32.2 Certification -- §906 - SOA'02 HTML 38K 15: R1 Document and Entity Information HTML 64K 16: R2 Consolidated Income Statements (Unaudited) HTML 149K 17: R3 Consolidated Comprehensive Income Statements HTML 67K (Unaudited) 18: R4 Consolidated Balance Sheets HTML 137K 19: R5 Consolidated Balance Sheets (Parenthetical) HTML 68K 20: R6 Consolidated Statements of Changes in Total Equity HTML 74K (Unaudited) 21: R7 Consolidated Cash Flow Statements (Unaudited) HTML 163K 22: R8 Introduction and Basis of Presentation HTML 52K 23: R9 Significant Accounting Policies HTML 66K 24: R10 Fair Value Disclosures HTML 1.00M 25: R11 Derivative Instruments and Hedging Activities HTML 550K 26: R12 Investment Securities HTML 465K 27: R13 Collateralized Transactions HTML 253K 28: R14 Loans and Allowance for Credit Losses HTML 298K 29: R15 Equity Method Investments HTML 53K 30: R16 Deposits HTML 59K 31: R17 Borrowings and Other Secured Financings HTML 68K 32: R18 Commitments, Guarantees and Contingencies HTML 218K 33: R19 Variable Interest Entities and Securitization HTML 349K Activities 34: R20 Regulatory Requirements HTML 176K 35: R21 Total Equity HTML 218K 36: R22 Earnings per Common Share HTML 82K 37: R23 Interest Income and Interest Expense HTML 68K 38: R24 Employee Benefit Plans HTML 53K 39: R25 Income Taxes HTML 45K 40: R26 Segment and Geographic Information HTML 180K 41: R27 Customer Contract Revenue Recognition HTML 108K 42: R28 Subsequent Events HTML 42K 43: R29 Significant Accounting Policies (Policy) HTML 62K 44: R30 Fair Value Disclosures (Tables) HTML 1.02M 45: R31 Derivative Instruments and Hedging Activities HTML 554K (Tables) 46: R32 Investment Securities (Tables) HTML 465K 47: R33 Collateralized Transactions (Tables) HTML 256K 48: R34 Loans and Allowance for Credit Losses (Tables) HTML 306K 49: R35 Equity Method Investments (Tables) HTML 51K 50: R36 Deposits (Tables) HTML 59K 51: R37 Borrowings and Other Secured Financings (Tables) HTML 67K 52: R38 Commitments, Guarantees and Contingencies (Tables) HTML 181K 53: R39 Variable Interest Entities and Securitization HTML 348K Activities (Tables) 54: R40 Regulatory Requirements (Tables) HTML 165K 55: R41 Total Equity (Tables) HTML 221K 56: R42 Earnings per Common Share (Tables) HTML 81K 57: R43 Interest Income and Interest Expense (Tables) HTML 66K 58: R44 Employee Benefit Plans (Tables) HTML 52K 59: R45 Segment and Geographic Information (Tables) HTML 185K 60: R46 Customer Contract Revenue Recognition (Tables) HTML 109K 61: R47 Significant Accounting Policies (Details) HTML 46K 62: R48 Fair Value Disclosures (Assets and Liabilities HTML 204K Measured at Fair Value on a Recurring Basis) (Details) 63: R49 Fair Value Disclosures (Rollforward of Level 3 HTML 170K Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) 64: R50 Fair Value Disclosures (Valuation Techniques and HTML 230K Sensitivity of Unobservable Inputs Used in Recurring Level 3 Fair Value Measurements) (Details) 65: R51 Fair Value Disclosures (Measured Based on Net HTML 61K Asset Value) (Details) 66: R52 Fair Value Disclosures (Earnings Impact of HTML 46K Instruments under the Fair Value Option) (Details) 67: R53 Fair Value Disclosures (Gains (Losses) Due to HTML 58K Changes in Instrument-Specific Credit Risk) (Details) 68: R54 Fair Value Disclosures (Borrowings Measured at HTML 54K Fair Value) (Details) 69: R55 Fair Value Disclosures (Excess of Contractual HTML 44K Principal Amount Over Fair Value) (Details) 70: R56 Fair Value Disclosures (Fair Value of Loans in HTML 42K Nonaccrual Status) (Details) 71: R57 Fair Value Disclosures (Assets Measured at Fair HTML 73K Value on a Non-Recurring Basis) (Details) 72: R58 Fair Value Disclosures (Financial Instruments Not HTML 126K Measured at Fair Value) (Details) 73: R59 Derivative Instruments and Hedging Activities HTML 185K (Derivative Fair Values) (Details) 74: R60 Derivative Instruments and Hedging Activities HTML 108K (Derivative Notionals) (Details) 75: R61 Derivative Instruments and Hedging Activities HTML 81K (Gains (Losses) on Accounting Hedges and Trading Revenues by Product Type) (Details) 76: R62 Derivative Instruments and Hedging Activities HTML 52K (Credit Risk-Related Contingencies) (Details) 77: R63 Derivative Instruments and Hedging Activities HTML 120K (Credit Derivatives and Other Credit Contracts) (Details) 78: R64 Investment Securities (AFS and HTM Securities) HTML 134K (Details) 79: R65 Investment Securities (Investment Securities in an HTML 147K Unrealized Loss Position) (Details) 80: R66 Investment Securities (Investment Securities by HTML 202K Contractual Maturity) (Details) 81: R67 Collateralized Transactions (Offsetting of Certain HTML 115K Collateralized Transactions) (Details) 82: R68 Collateralized Transactions (Gross Secured HTML 85K Financing Balances) (Details) 83: R69 Collateralized Transactions (Assets Pledged) HTML 45K (Details) 84: R70 Collateralized Transactions (Collateral Received) HTML 43K (Details) 85: R71 Collateralized Transactions (Customer Margin HTML 39K Lending and Other) (Details) 86: R72 Collateralized Transactions (Restricted Cash and HTML 46K Segregated Securities) (Details) 87: R73 Loans and Allowance for Credit Losses (Loans Held HTML 126K for Investment and Held for Sale) (Details) 88: R74 Loans and Allowance for Credit Losses (Impaired HTML 66K Loans) (Details) 89: R75 Loans and Allowance for Credit Losses (Tdr) HTML 43K (Details) 90: R76 Loans and Allowance for Credit Losses (Allowance HTML 92K for Loan Losses and Lending Commitments Rollforward) (Details) 91: R77 Loans and Allowance for Credit Losses (Employee HTML 49K Loans) (Details) 92: R78 Equity Method Investments (Equity Method HTML 45K Investment Balances) (Details) 93: R79 Equity Method Investments (Investees) (Details) HTML 49K 94: R80 Deposits (Details) HTML 63K 95: R81 Borrowings and Other Secured Financings (Long-Term HTML 55K Borrowings) (Details) 96: R82 Borrowings and Other Secured Financings (Other HTML 46K Secured Financings) (Details) 97: R83 Commitments, Guarantees and Contingencies HTML 79K (Commitments) (Details) 98: R84 Commitments, Guarantees and Contingencies HTML 111K (Obligations under Guarantee Arrangements) (Details) 99: R85 Commitments, Guarantees and Contingencies HTML 105K (Contingencies) (Details) 100: R86 Variable Interest Entities and Securitization HTML 50K Activities (Consolidated VIEs) (Details) 101: R87 Variable Interest Entities and Securitization HTML 76K Activities (Assets and Liabilities by Balance Sheet Caption) (Details) 102: R88 Variable Interest Entities and Securitization HTML 102K Activities (Non-Consolidated VIEs) (Details) 103: R89 Variable Interest Entities and Securitization HTML 85K Activities (Transfers of Assets with Continuing Involvement 1) (Details) 104: R90 Variable Interest Entities and Securitization HTML 70K Activities (Transfers of Assets with Continuing Involvement 2) (Details) 105: R91 Variable Interest Entities and Securitization HTML 50K Activities (Proceeds from New Securitization Transactions and Sales of Loans) (Details) 106: R92 Variable Interest Entities and Securitization HTML 53K Activities (Assets Sold with Retained Exposure) (Details) 107: R93 Variable Interest Entities and Securitization HTML 42K Activities (Failed Sales) (Details) 108: R94 Regulatory Requirements (Narrative) (Details) HTML 45K 109: R95 Regulatory Requirements (Capital Measures) HTML 82K (Details) 110: R96 Regulatory Requirements (U.S. Bank Subsidiaries' HTML 86K Regulatory Capital and Capital Ratios) (Details) 111: R97 Regulatory Requirements (Broker-Dealer Regulatory HTML 47K Capital Requirements) (Details) 112: R98 Total Equity (Dividends and Share Repurchases) HTML 56K (Details) 113: R99 Total Equity (Preferred Stock General Disclosure) HTML 42K (Details) 114: R100 Total Equity (Preferred Stock Outstanding) HTML 83K (Details) 115: R101 Total Equity (Aoci) (Details) HTML 59K 116: R102 Total Equity (Components of Period Changes in OCI HTML 175K ) (Details) 117: R103 Total Equity (Cumulative Adjustments to Retained HTML 51K Earnings) (Details) 118: R104 Earnings per Common Share (Calculation of Basic HTML 101K and Diluted EPS) (Details) 119: R105 Interest Income and Interest Expense (Details) HTML 66K 120: R106 Employee Benefit Plans (Net Periodic Benefit HTML 53K Expense (Income)) (Details) 121: R107 Segment and Geographic Information (Selected HTML 97K Financial Information by Business Segment) (Details) 122: R108 Segment and Geographic Information (Assets by HTML 47K Business Segment) (Details) 123: R109 Segment and Geographic Information (Additional HTML 43K Information - Investment Management) (Details) 124: R110 Segment and Geographic Information (Net Revenues HTML 46K by Region) (Details) 125: R111 Customer Contract Revenue Recognition (Customer HTML 81K Contract Renenues) (Details) 126: R112 Customer Contract Revenue Recognition (Change in HTML 63K Revenue) (Details) 127: R113 Customer Contract Revenue Recognition (Balance HTML 51K Sheet Amounts) (Details) 128: R114 Customer Contract Revenue Recognition (Future HTML 49K Expected Revenues) (Details) 130: XML IDEA XML File -- Filing Summary XML 262K 129: EXCEL IDEA Workbook of Financial Reports XLSX 196K 9: EX-101.INS XBRL Instance -- ms-20180331 XML 13.13M 11: EX-101.CAL XBRL Calculations -- ms-20180331_cal XML 640K 12: EX-101.DEF XBRL Definitions -- ms-20180331_def XML 3.52M 13: EX-101.LAB XBRL Labels -- ms-20180331_lab XML 6.88M 14: EX-101.PRE XBRL Presentations -- ms-20180331_pre XML 4.78M 10: EX-101.SCH XBRL Schema -- ms-20180331 XSD 699K 131: ZIP XBRL Zipped Folder -- 0001193125-18-152899-xbrl Zip 913K
EX-31.2 |
EXHIBIT 31.2
Certification
I, Jonathan Pruzan, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Morgan Stanley; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 4, 2018
/S/ JONATHAN PRUZAN |
Jonathan Pruzan |
Executive Vice President and Chief Financial Officer |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 5/4/18 | 424B2, FWP | ||
For Period end: | 3/31/18 | 13F-HR, 13F-HR/A, FWP | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/22/24 Morgan Stanley 10-K 12/31/23 224:45M 2/24/23 Morgan Stanley 10-K 12/31/22 227:50M 2/24/22 Morgan Stanley 10-K 12/31/21 225:51M 2/26/21 Morgan Stanley 10-K 12/31/20 225:50M |